Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

Clinical Cancer Research

Volumn 16, Issue 21, 2010, Pages 5303-5311

  Rosenblat, Todd L ^a   McDevitt, Michael R ^a   Mulford, Deborah A ^a   Pandit Taskar, Neeta ^a   Divgi, Chaitanya R ^a   Panageas, Katherine S ^a   Heaney, Mark L ^a   Chanel, Suzanne ^a   Morgenstern, Alfred ^b   Sgouros, George ^a   Larson, Steven M ^a   Scheinberg, David A ^a   Jurcic, Joseph G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; HUM 195; LINTUZUMAB BI 213; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALPHA RADIATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANDIDEMIA; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG FEVER; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; BISMUTH; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOISOTOPES; REMISSION INDUCTION;

EID: 78049456138     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0382     Document Type: Article

References (37)

1. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649-56.
2. Stockerl-Goldstein KE, Blume KG. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. Oxford: Blackwell Science, Inc.; 1999, p. 823-34.
3. Horner MJ, Ries LAG, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2006. Bethesda (MD): National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER Web site, 2009.
4. Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003;32:549-56.
5. Jurcic JG, Divgi CR, McDevitt MR, et al. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. Proc Am Soc Clin Oncol 2000;19:8a.
6. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med 1998;25:1237-47.
7. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983;62:124-32.
8. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984;8:521-34.
9. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992;52:6761-7.
10. Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994;83:1760-8.
11. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000;6:372-80.
12. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 1998;4:1421-8. (Pubitemid 28265224)
13. Feldman E, Kalaycio M, Weiner G, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003;17:314-8.
14. Raza A, Jurcic JG, Roboz GJ, et al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma 2009;50:1336-44.
15. Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9.
16. Brechbiel MW, Gansow OA. Synthesis of C-functionalized transcyclohexyl-diethylenetriaminepentaacetic acids for labeling of monoclonal antibodies with the bismuth-212 α-particle emitter. J Chem Soc Perkin Trans 1992;1:1173-8.
17. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 1995;22:387-90.
18. Mirzadeh S, Brechbiel MW, Atcher RW, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetriaminepentaacetic acid ligand to immunoglobulin. Bioconjug Chem 1990;1:59-65.
19. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA monoclonal antibody conjugates. Bioconjug Chem 1992;3:342-5.
20. Nikula TK, McDevitt MR, Finn RD, et al. α-Emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999;40:166-76.
21. 213Bi-labeled antibody constructs for clinical use. J Nucl Med 1999;40:1722-7.
22. Finn RD, McDevitt MR, Scheinberg DA, et al. Refinements and improvements for Bi-213 production and use as a targeted therapeutic radiopharmaceutical. J Labelled Compds Radiopharm 1997;40:293.
23. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isot 1999;50:895-904.
24. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.
25. 213Bi- HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935-46.
26. Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, Larson SM, Sgouros G. Parametric images of antibody pharmacokinetics in Bi-213-HuM195 therapy of leukemia. J Nucl Med 2001;42:27-32.
27. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9.
28. Charlson ME, Pompie P III, Ales K, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
29. Etienne A, Esterni B, Charonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007;109:1376-83.
30. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
31. Bodey GP, Coltman CA, Freireich EJ, et al. Chemotherapy of acute leukemia: comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide. Arch Intern Med 1974;133:260-6.
32. Bodey GP, Freireich EJ, Monto RW, et al. Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemother Rep 1969;53:59-66.
33. Bickers JN, Gehan EA, Freireich EJ, et al. Cytarabine for acute leukemia in adults: effect of schedule on therapeutic response. Arch Intern Med 1974;133:251-9.
34. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24.
35. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005;23:4110-6.
36. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-52.
37. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-40.